Takaaki Mizuno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Takaaki Mizuno has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Yuichiro Ohe
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
4 shared publications- Jun Sato
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
3 shared publications - Makoto Hirata
Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan
3 shared publications - Noboru Yamamoto
Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
3 shared publications - Noriko Tanabe
Department of Genetic Medicine and Services National Cancer Center Hospital Chuo‐ku Tokyo Japan
3 shared publications - Ryuji Hamamoto
Department of NCC Cancer Science, Biomedical Science and Engineering Track, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8658
Feasibility, Safety, Adherence, and Functional Outcomes of a Mobile Application-Facilitated, Unsupervised Remote Cardiac Rehabilitation Program with Exercise Intensity Optimization: A Single-Arm Clinical Trial
Background/Objectives: Cardiac rehabilitation (CR) is essential for patients with cardiovascular disease (CVD); however, participation rates remain low because of logistical barriers. We developed a mobile application-facilitated, unsupervised remote CR program with exercise intensity optimization and multidisciplinary support. This study aimed to evaluate its feasibility, safety, adherence, and associated changes in functional capacity among patients with CVD. Methods: This single-center, single-arm interventional study (jRCTs042230018) enrolled 30 patients with CVD who followed an unsupervised, home-based, mobile application-facilitated CR program for 5 months, with multidisciplinary video counseling every 2 weeks. The primary outcome was the relative change in the 6-min walk distance (6MWD). Secondary outcomes included changes in peak oxygen uptake (VO2), ventilatory anaerobic threshold (VAT), ventilation-to-carbon dioxide output slope, and Hospital Anxiety and Depression Scale (HADS) score, as well as program adherence. Results: All participants completed the 5-month follow-up and performed a median of 58.5 (interquartile range: 28.0, 77.8) sessions, corresponding to 89.5% (42.8, 118.6) of prescribed sessions (three per week). 6MWD improved from 468.3 ± 98.8 m to 542.6 ± 70.3 m; the mean absolute change was 74.3 m (95% CI, 47.8–100.7; relative change, 18.6%; p < 0.001). Peak VO2 and VAT increased by 16.7% and 30.1%, respectively. HADS scores decreased modestly. One participant was hospitalized for worsening heart failure (unrelated to the intervention); no other serious cardiovascular events occurred. Conclusions: This mobile application-based, unsupervised remote CR program was feasible and associated with improved exercise capacity in patients with CVD. Randomized trials comparing it with center-based CR are warranted.
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8658
Open AccessFeasibility, Safety, Adherence, and Functional Outcomes of a Mobile Application-Facilitated, Unsupervised Remote Cardiac Rehabilitation Program with Exercise Intensity Optimization: A Single-Arm Clinical Trial
Background/Objectives: Cardiac rehabilitation (CR) is essential for patients with cardiovascular disease (CVD); however, participation rates remain low because of logistical barriers. We developed a mobile application-facilitated, unsupervised remote CR program with exercise intensity optimization and multidisciplinary support. This study aimed to evaluate its feasibility, safety, adherence, and associated changes in functional capacity among patients with CVD. Methods: This single-center, single-arm interventional study (jRCTs042230018) enrolled 30 patients with CVD who followed an unsupervised, home-based, mobile application-facilitated CR program for 5 months, with multidisciplinary video counseling every 2 weeks. The primary outcome was the relative change in the 6-min walk distance (6MWD). Secondary outcomes included changes in peak oxygen uptake (VO2), ventilatory anaerobic threshold (VAT), ventilation-to-carbon dioxide output slope, and Hospital Anxiety and Depression Scale (HADS) score, as well as program adherence. Results: All participants completed the 5-month follow-up and performed a median of 58.5 (interquartile range: 28.0, 77.8) sessions, corresponding to 89.5% (42.8, 118.6) of prescribed sessions (three per week). 6MWD improved from 468.3 ± 98.8 m to 542.6 ± 70.3 m; the mean absolute change was 74.3 m (95% CI, 47.8–100.7; relative change, 18.6%; p < 0.001). Peak VO2 and VAT increased by 16.7% and 30.1%, respectively. HADS scores decreased modestly. One participant was hospitalized for worsening heart failure (unrelated to the intervention); no other serious cardiovascular events occurred. Conclusions: This mobile application-based, unsupervised remote CR program was feasible and associated with improved exercise capacity in patients with CVD. Randomized trials comparing it with center-based CR are warranted.
- Open Access
- 11 June 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-17
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations
Background: In an extensive genomic analysis of lung adenocarcinomas (LUADs), driver mutations have been recognized as potential targets for molecular therapy. However, there remain cases where target genes are not identified. Super-enhancers and structural variants are frequently identified in several hundred loci per case. Despite this, most cancer research has approached the analysis of these data sets separately, without merging and comparing the data, and there are no examples of integrated analysis in LUAD. Methods: We performed an integrated analysis of super-enhancers and structural variants in a cohort of 174 LUAD cases that lacked clinically actionable genetic alterations. To achieve this, we conducted both WGS and H3K27Ac ChIP-seq analyses using samples with driver gene mutations and those without, allowing for a comprehensive investigation of the potential roles of super-enhancer in LUAD cases. Results: We demonstrate that most genes situated in these overlapped regions were associated with known and previously unknown driver genes and aberrant expression resulting from the formation of super-enhancers accompanied by genomic structural abnormalities. Hi-C and long-read sequencing data further corroborated this insight. When we employed CRISPR-Cas9 to induce structural abnormalities that mimicked cases with outlier ERBB2 gene expression, we observed an elevation in ERBB2 expression. These abnormalities are associated with a higher risk of recurrence after surgery, irrespective of the presence or absence of driver mutations. Conclusions: Our findings suggest that aberrant gene expression linked to structural polymorphisms can significantly impact personalized cancer treatment by facilitating the identification of driver mutations and prognostic factors, contributing to a more comprehensive understanding of LUAD pathogenesis.
- 11 June 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-17
Open AccessMechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations
Background: In an extensive genomic analysis of lung adenocarcinomas (LUADs), driver mutations have been recognized as potential targets for molecular therapy. However, there remain cases where target genes are not identified. Super-enhancers and structural variants are frequently identified in several hundred loci per case. Despite this, most cancer research has approached the analysis of these data sets separately, without merging and comparing the data, and there are no examples of integrated analysis in LUAD. Methods: We performed an integrated analysis of super-enhancers and structural variants in a cohort of 174 LUAD cases that lacked clinically actionable genetic alterations. To achieve this, we conducted both WGS and H3K27Ac ChIP-seq analyses using samples with driver gene mutations and those without, allowing for a comprehensive investigation of the potential roles of super-enhancer in LUAD cases. Results: We demonstrate that most genes situated in these overlapped regions were associated with known and previously unknown driver genes and aberrant expression resulting from the formation of super-enhancers accompanied by genomic structural abnormalities. Hi-C and long-read sequencing data further corroborated this insight. When we employed CRISPR-Cas9 to induce structural abnormalities that mimicked cases with outlier ERBB2 gene expression, we observed an elevation in ERBB2 expression. These abnormalities are associated with a higher risk of recurrence after surgery, irrespective of the presence or absence of driver mutations. Conclusions: Our findings suggest that aberrant gene expression linked to structural polymorphisms can significantly impact personalized cancer treatment by facilitating the identification of driver mutations and prognostic factors, contributing to a more comprehensive understanding of LUAD pathogenesis.
- Open Access
- 8 December 2023
- Published by Elsevier in Medical Image Analysis
- Vol. 92, 103060
Sketch-based semantic retrieval of medical images
- 8 December 2023
- Published by Elsevier in Medical Image Analysis
- Vol. 92, 103060
Open AccessSketch-based semantic retrieval of medical images
- Open Access
- 14 November 2023
- Published by American Association for Cancer Research (AACR)
Data from Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the genomic information and clinical characteristics of 23,928 patients with solid cancers who underwent either tumor-only (n = 20,189) or paired tumor-normal (n = 3,739) sequencing CGP tests between June 2019 and December 2021 using the comprehensive national database. We assigned clinical significance for all variants and highlighted the prevalence and characteristics of PGVs. Our primary analysis of the tumor-normal sequencing cohort revealed that 152 patients (4.1%) harbored PGVs in 15 CSGs. Among 783 germline variants, 113 were annotated as PGVs, 70 as benign variants, and 600 as variants of uncertain significance. The number of PGVs identified was highest in BRCA1/2, with 56, followed by TP53, with 18. PGVs were the most prevalent in ovarian and peritoneal cancers, including among cancer types common in Asia. In the tumor-only sequencing cohort, of the 5,184 pathogenic somatic variants across 26 CSGs, 784 (15.1%) were extracted according to the European Society for Medical Oncology recommendations for germline-focused tumor analysis. The prevalence of PGVs was similar to that previously reported in Europe and the United States. This is the largest analysis based on real-world tumor-normal sequencing tests in Asia. The more widespread use of the tumor-normal sequencing CGP test could be reasonable for evaluating PGVs.Significance:We analyzed real-world data from over 23,000 patients in Japan, revealing 4.1% harbored PGVs, particularly in BRCA1/2 and TP53, in CSGs. It highlights the prevalence of PGVs in Asian populations and supports the broader adoption of tumor-normal sequencing CGP tests for PGV evaluation.
- 14 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the genomic information and clinical characteristics of 23,928 patients with solid cancers who underwent either tumor-only (n = 20,189) or paired tumor-normal (n = 3,739) sequencing CGP tests between June 2019 and December 2021 using the comprehensive national database. We assigned clinical significance for all variants and highlighted the prevalence and characteristics of PGVs. Our primary analysis of the tumor-normal sequencing cohort revealed that 152 patients (4.1%) harbored PGVs in 15 CSGs. Among 783 germline variants, 113 were annotated as PGVs, 70 as benign variants, and 600 as variants of uncertain significance. The number of PGVs identified was highest in BRCA1/2, with 56, followed by TP53, with 18. PGVs were the most prevalent in ovarian and peritoneal cancers, including among cancer types common in Asia. In the tumor-only sequencing cohort, of the 5,184 pathogenic somatic variants across 26 CSGs, 784 (15.1%) were extracted according to the European Society for Medical Oncology recommendations for germline-focused tumor analysis. The prevalence of PGVs was similar to that previously reported in Europe and the United States. This is the largest analysis based on real-world tumor-normal sequencing tests in Asia. The more widespread use of the tumor-normal sequencing CGP test could be reasonable for evaluating PGVs.Significance:We analyzed real-world data from over 23,000 patients in Japan, revealing 4.1% harbored PGVs, particularly in BRCA1/2 and TP53, in CSGs. It highlights the prevalence of PGVs in Asian populations and supports the broader adoption of tumor-normal sequencing CGP tests for PGV evaluation.
- Open Access
- 14 November 2023
- Published by American Association for Cancer Research (AACR)
Data from Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the genomic information and clinical characteristics of 23,928 patients with solid cancers who underwent either tumor-only (n = 20,189) or paired tumor-normal (n = 3,739) sequencing CGP tests between June 2019 and December 2021 using the comprehensive national database. We assigned clinical significance for all variants and highlighted the prevalence and characteristics of PGVs. Our primary analysis of the tumor-normal sequencing cohort revealed that 152 patients (4.1%) harbored PGVs in 15 CSGs. Among 783 germline variants, 113 were annotated as PGVs, 70 as benign variants, and 600 as variants of uncertain significance. The number of PGVs identified was highest in BRCA1/2, with 56, followed by TP53, with 18. PGVs were the most prevalent in ovarian and peritoneal cancers, including among cancer types common in Asia. In the tumor-only sequencing cohort, of the 5,184 pathogenic somatic variants across 26 CSGs, 784 (15.1%) were extracted according to the European Society for Medical Oncology recommendations for germline-focused tumor analysis. The prevalence of PGVs was similar to that previously reported in Europe and the United States. This is the largest analysis based on real-world tumor-normal sequencing tests in Asia. The more widespread use of the tumor-normal sequencing CGP test could be reasonable for evaluating PGVs.Significance:We analyzed real-world data from over 23,000 patients in Japan, revealing 4.1% harbored PGVs, particularly in BRCA1/2 and TP53, in CSGs. It highlights the prevalence of PGVs in Asian populations and supports the broader adoption of tumor-normal sequencing CGP tests for PGV evaluation.
- 14 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the genomic information and clinical characteristics of 23,928 patients with solid cancers who underwent either tumor-only (n = 20,189) or paired tumor-normal (n = 3,739) sequencing CGP tests between June 2019 and December 2021 using the comprehensive national database. We assigned clinical significance for all variants and highlighted the prevalence and characteristics of PGVs. Our primary analysis of the tumor-normal sequencing cohort revealed that 152 patients (4.1%) harbored PGVs in 15 CSGs. Among 783 germline variants, 113 were annotated as PGVs, 70 as benign variants, and 600 as variants of uncertain significance. The number of PGVs identified was highest in BRCA1/2, with 56, followed by TP53, with 18. PGVs were the most prevalent in ovarian and peritoneal cancers, including among cancer types common in Asia. In the tumor-only sequencing cohort, of the 5,184 pathogenic somatic variants across 26 CSGs, 784 (15.1%) were extracted according to the European Society for Medical Oncology recommendations for germline-focused tumor analysis. The prevalence of PGVs was similar to that previously reported in Europe and the United States. This is the largest analysis based on real-world tumor-normal sequencing tests in Asia. The more widespread use of the tumor-normal sequencing CGP test could be reasonable for evaluating PGVs.Significance:We analyzed real-world data from over 23,000 patients in Japan, revealing 4.1% harbored PGVs, particularly in BRCA1/2 and TP53, in CSGs. It highlights the prevalence of PGVs in Asian populations and supports the broader adoption of tumor-normal sequencing CGP tests for PGV evaluation.
- Open Access
- 14 November 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (11) , 2302-2311
Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the genomic information and clinical characteristics of 23,928 patients with solid cancers who underwent either tumor-only (n = 20,189) or paired tumor-normal (n = 3,739) sequencing CGP tests between June 2019 and December 2021 using the comprehensive national database. We assigned clinical significance for all variants and highlighted the prevalence and characteristics of PGVs. Our primary analysis of the tumor-normal sequencing cohort revealed that 152 patients (4.1%) harbored PGVs in 15 CSGs. Among 783 germline variants, 113 were annotated as PGVs, 70 as benign variants, and 600 as variants of uncertain significance. The number of PGVs identified was highest in BRCA1/2, with 56, followed by TP53, with 18. PGVs were the most prevalent in ovarian and peritoneal cancers, including among cancer types common in Asia. In the tumor-only sequencing cohort, of the 5,184 pathogenic somatic variants across 26 CSGs, 784 (15.1%) were extracted according to the European Society for Medical Oncology recommendations for germline-focused tumor analysis. The prevalence of PGVs was similar to that previously reported in Europe and the United States. This is the largest analysis based on real-world tumor-normal sequencing tests in Asia. The more widespread use of the tumor-normal sequencing CGP test could be reasonable for evaluating PGVs. Significance: We analyzed real-world data from over 23,000 patients in Japan, revealing 4.1% harbored PGVs, particularly in BRCA1/2 and TP53, in CSGs. It highlights the prevalence of PGVs in Asian populations and supports the broader adoption of tumor-normal sequencing CGP tests for PGV evaluation.
- 14 November 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (11) , 2302-2311
Open AccessPathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the genomic information and clinical characteristics of 23,928 patients with solid cancers who underwent either tumor-only (n = 20,189) or paired tumor-normal (n = 3,739) sequencing CGP tests between June 2019 and December 2021 using the comprehensive national database. We assigned clinical significance for all variants and highlighted the prevalence and characteristics of PGVs. Our primary analysis of the tumor-normal sequencing cohort revealed that 152 patients (4.1%) harbored PGVs in 15 CSGs. Among 783 germline variants, 113 were annotated as PGVs, 70 as benign variants, and 600 as variants of uncertain significance. The number of PGVs identified was highest in BRCA1/2, with 56, followed by TP53, with 18. PGVs were the most prevalent in ovarian and peritoneal cancers, including among cancer types common in Asia. In the tumor-only sequencing cohort, of the 5,184 pathogenic somatic variants across 26 CSGs, 784 (15.1%) were extracted according to the European Society for Medical Oncology recommendations for germline-focused tumor analysis. The prevalence of PGVs was similar to that previously reported in Europe and the United States. This is the largest analysis based on real-world tumor-normal sequencing tests in Asia. The more widespread use of the tumor-normal sequencing CGP test could be reasonable for evaluating PGVs. Significance: We analyzed real-world data from over 23,000 patients in Japan, revealing 4.1% harbored PGVs, particularly in BRCA1/2 and TP53, in CSGs. It highlights the prevalence of PGVs in Asian populations and supports the broader adoption of tumor-normal sequencing CGP tests for PGV evaluation.
- Open Access
Sketch-based Medical Image Retrieval
The amount of medical images stored in hospitals is increasing faster than ever; however, utilizing the accumulated medical images has been limited. This is because existing content-based medical image retrieval (CBMIR) systems usually require example images to construct query vectors; nevertheless, example images cannot always be prepared. Besides, there can be images with rare characteristics that make it difficult to find similar example images, which we call isolated samples. Here, we introduce a novel sketch-based medical image retrieval (SBMIR) system that enables users to find images of interest without example images. The key idea lies in feature decomposition of medical images, whereby the entire feature of a medical image can be decomposed into and reconstructed from normal and abnormal features. By extending this idea, our SBMIR system provides an easy-to-use two-step graphical user interface: users first select a template image to specify a normal feature and then draw a semantic sketch of the disease on the template image to represent an abnormal feature. Subsequently, it integrates the two kinds of input to construct a query vector and retrieves reference images with the closest reference vectors. Using two datasets, ten healthcare professionals with various clinical backgrounds participated in the user test for evaluation. As a result, our SBMIR system enabled users to overcome previous challenges, including image retrieval based on fine-grained image characteristics, image retrieval without example images, and image retrieval for isolated samples. Our SBMIR system achieves flexible medical image retrieval on demand, thereby expanding the utility of medical image databases.
Open AccessSketch-based Medical Image Retrieval
The amount of medical images stored in hospitals is increasing faster than ever; however, utilizing the accumulated medical images has been limited. This is because existing content-based medical image retrieval (CBMIR) systems usually require example images to construct query vectors; nevertheless, example images cannot always be prepared. Besides, there can be images with rare characteristics that make it difficult to find similar example images, which we call isolated samples. Here, we introduce a novel sketch-based medical image retrieval (SBMIR) system that enables users to find images of interest without example images. The key idea lies in feature decomposition of medical images, whereby the entire feature of a medical image can be decomposed into and reconstructed from normal and abnormal features. By extending this idea, our SBMIR system provides an easy-to-use two-step graphical user interface: users first select a template image to specify a normal feature and then draw a semantic sketch of the disease on the template image to represent an abnormal feature. Subsequently, it integrates the two kinds of input to construct a query vector and retrieves reference images with the closest reference vectors. Using two datasets, ten healthcare professionals with various clinical backgrounds participated in the user test for evaluation. As a result, our SBMIR system enabled users to overcome previous challenges, including image retrieval based on fine-grained image characteristics, image retrieval without example images, and image retrieval for isolated samples. Our SBMIR system achieves flexible medical image retrieval on demand, thereby expanding the utility of medical image databases.
- Open Access
- 7 October 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (6) , 1
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
HER3 (erbB3) signaling serves an important role in the development and chemoresistance of ovarian cancer, and is activated by chemotherapy. To evaluate the influence of neoadjuvant chemotherapy and other clinical factors on the expression of HER3, as well as to examine its role as a prognostic marker, the present study evaluated archived tissues from patients who underwent surgery for ovarian cancer between 2011 and 2018 at our hospital. Immunohistochemical staining for HER3 was performed using formalin‑fixed paraffin‑embedded surgical specimens and biopsy samples. In total, data from 111 patients with sufficient surgically resected tumor samples were extracted. A total of 28 patients with histology type high‑grade serous carcinoma (HGSC) had specimens available from both pre‑chemotherapy biopsies and post‑chemotherapy surgery. High HER3 expression (HER3‑high) was observed in 64 patients (58%), whereas low HER3 expression (HER3‑low) was observed in 47 patients (42%). Multivariate logistic regression analysis identified neoadjuvant chemotherapy [odds ratio (OR), 7.49; 95% confidence interval (CI), 2.48‑22.64; P<0.001) and non‑HGSC histology (OR, 5.42; 95% CI, 1.99‑14.78; P<0.001) as significant predictive factors for HER3‑high. In pre‑chemotherapy biopsy specimens, 15 patients were HER3‑high and 13 were HER3‑low. After chemotherapy, eight of 13 patients with HER3‑low exhibited a change in status to HER3‑high, with a trend toward poorer progression‑free survival compared to that of patients whose status remained HER3‑low. In conclusion, HER3 overexpression was revealed to be common among patients with ovarian cancer, especially in those with non‑HGSC histology. In addition, HER3 expression may be promoted by chemotherapy. These findings suggested that patients with ovarian cancer are good candidates for emerging HER3‑targeting therapies.
- 7 October 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (6) , 1
Open AccessNeoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
HER3 (erbB3) signaling serves an important role in the development and chemoresistance of ovarian cancer, and is activated by chemotherapy. To evaluate the influence of neoadjuvant chemotherapy and other clinical factors on the expression of HER3, as well as to examine its role as a prognostic marker, the present study evaluated archived tissues from patients who underwent surgery for ovarian cancer between 2011 and 2018 at our hospital. Immunohistochemical staining for HER3 was performed using formalin‑fixed paraffin‑embedded surgical specimens and biopsy samples. In total, data from 111 patients with sufficient surgically resected tumor samples were extracted. A total of 28 patients with histology type high‑grade serous carcinoma (HGSC) had specimens available from both pre‑chemotherapy biopsies and post‑chemotherapy surgery. High HER3 expression (HER3‑high) was observed in 64 patients (58%), whereas low HER3 expression (HER3‑low) was observed in 47 patients (42%). Multivariate logistic regression analysis identified neoadjuvant chemotherapy [odds ratio (OR), 7.49; 95% confidence interval (CI), 2.48‑22.64; P<0.001) and non‑HGSC histology (OR, 5.42; 95% CI, 1.99‑14.78; P<0.001) as significant predictive factors for HER3‑high. In pre‑chemotherapy biopsy specimens, 15 patients were HER3‑high and 13 were HER3‑low. After chemotherapy, eight of 13 patients with HER3‑low exhibited a change in status to HER3‑high, with a trend toward poorer progression‑free survival compared to that of patients whose status remained HER3‑low. In conclusion, HER3 overexpression was revealed to be common among patients with ovarian cancer, especially in those with non‑HGSC histology. In addition, HER3 expression may be promoted by chemotherapy. These findings suggested that patients with ovarian cancer are good candidates for emerging HER3‑targeting therapies.
- Open Access
- 23 July 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (4) , 1
HER3 protein expression as a risk factor for post‑operative recurrence in patients with early‑stage adenocarcinoma and adenosquamous carcinoma of the cervix
Patients with cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) have a poorer prognosis than those with squamous cell carcinoma (SCC). Erb‑b2 receptor tyrosine kinase 3 (HER3) is a member of the epidermal growth factor receptor family and its expression is associated with unfavorable prognosis in several cancer types, including SCC of the cervix. As there is limited information on the prognostic value of HER3 for AC and ASC of the cervix, the present study aimed to evaluate the expression of HER3 and its impact on post‑operative recurrence in patients with AC and ASC of the cervix. This retrospective study included 39 patients with early‑stage AC and ASC who underwent primary surgery between January 1997 and December 2017. Immunohistochemical staining for HER3 was performed on formalin‑fixed paraffin‑embedded surgical specimens. The possible influence of HER3 expression on disease‑free survival (DFS) was studied by using multivariate Cox regression with adjustment for established risk factors of post‑operative recurrence. High expression of HER3 (HER3‑high) was detected in 85.1% of cases of AC (23/27) and in 58.3% of cases of ASC (7/12). The median follow‑up duration was 63.1 months and Kaplan‑Meier analysis indicated that the 5‑year DFS rates of patients with AC and ASC of the cervix were 56.7% in patients with HER3‑high and 77.8% in patients with HER3‑low (log rank, P=0.20). On multivariate analysis, HER3‑high [hazard ratio (HR)=6.32, 95% CI: 1.10‑36.26, P=0.039), pelvic lymph node metastasis (HR=7.61, 95% CI: 2.07‑28.00, P=0.002) and vascular invasion (HR=4.28, 95% CI: 1.12‑16.31, P=0.033) were indicated to be independent predictors of DFS. To date, the present study is the most comprehensive analysis to evaluate the expression of HER3 in patients with early‑stage AC and ASC of the cervix. The results suggested that HER3 overexpression may be an independent risk factor for post‑operative recurrence. However, these results and the prognostic value of HER3 should be confirmed in a larger sample.
- 23 July 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (4) , 1
Open AccessHER3 protein expression as a risk factor for post‑operative recurrence in patients with early‑stage adenocarcinoma and adenosquamous carcinoma of the cervix
Patients with cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) have a poorer prognosis than those with squamous cell carcinoma (SCC). Erb‑b2 receptor tyrosine kinase 3 (HER3) is a member of the epidermal growth factor receptor family and its expression is associated with unfavorable prognosis in several cancer types, including SCC of the cervix. As there is limited information on the prognostic value of HER3 for AC and ASC of the cervix, the present study aimed to evaluate the expression of HER3 and its impact on post‑operative recurrence in patients with AC and ASC of the cervix. This retrospective study included 39 patients with early‑stage AC and ASC who underwent primary surgery between January 1997 and December 2017. Immunohistochemical staining for HER3 was performed on formalin‑fixed paraffin‑embedded surgical specimens. The possible influence of HER3 expression on disease‑free survival (DFS) was studied by using multivariate Cox regression with adjustment for established risk factors of post‑operative recurrence. High expression of HER3 (HER3‑high) was detected in 85.1% of cases of AC (23/27) and in 58.3% of cases of ASC (7/12). The median follow‑up duration was 63.1 months and Kaplan‑Meier analysis indicated that the 5‑year DFS rates of patients with AC and ASC of the cervix were 56.7% in patients with HER3‑high and 77.8% in patients with HER3‑low (log rank, P=0.20). On multivariate analysis, HER3‑high [hazard ratio (HR)=6.32, 95% CI: 1.10‑36.26, P=0.039), pelvic lymph node metastasis (HR=7.61, 95% CI: 2.07‑28.00, P=0.002) and vascular invasion (HR=4.28, 95% CI: 1.12‑16.31, P=0.033) were indicated to be independent predictors of DFS. To date, the present study is the most comprehensive analysis to evaluate the expression of HER3 in patients with early‑stage AC and ASC of the cervix. The results suggested that HER3 overexpression may be an independent risk factor for post‑operative recurrence. However, these results and the prognostic value of HER3 should be confirmed in a larger sample.
- Open Access
- 20 February 2020
- Published by Wiley in Thoracic Cancer
- Vol. 11 (4) , 1038-1044
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure
Background Several studies have previously demonstrated the survival benefit of both EGFR‐TKI treatment and chemotherapy in patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR‐TKI therapy, focusing on the number of organs with metastasis (hereafter, metastatic organs). Methods Between January 2010 and December 2016, consecutive patients with EGFR‐mutated NSCLC who were started on first‐line EGFR‐TKI were reviewed. The factors influencing withholding systemic chemotherapy and the post‐progression survival (PPS) after failure of EGFR‐TKI were investigated. Results A total of 393 patients were started on first‐line EGFR‐TKI during the study period. After excluding patients maintained on EGFR‐TKI or who received osimertinib targeting secondary EGFR T790M, 297 patients were included in the analysis. Among these, 180 (60.6%) received chemotherapy after failure of EGFR‐TKI (TKI‐Ct group), while the remaining 117 (39.4%) received no chemotherapy (TKI‐only group). Multivariate analysis identified older age (≥75 years: odds ratio [OR] = 0.25, 95% confidence interval [CI]: 0.11–0.43, P < 0.001), poor performance status (PS) (≥2: OR = 0.06, 95% CI: 0.03–0.15, P < 0.001), and three or more metastatic organs (OR = 0.42, 95% CI: 0.22–0.80, P = 0.008) as being significantly associated with withholding of chemotherapy after failure of EGFR‐TKI. Conclusion A relatively large number of metastatic organs and a poor PS were associated with the withholding of subsequent chemotherapy after failure of EGFR‐TKI in EGFR‐mutated NSCLC patients. Further research for patients with such a poor prognosis should be investigated in the future.
- 20 February 2020
- Published by Wiley in Thoracic Cancer
- Vol. 11 (4) , 1038-1044
Open AccessNumber of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure
Background Several studies have previously demonstrated the survival benefit of both EGFR‐TKI treatment and chemotherapy in patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR‐TKI therapy, focusing on the number of organs with metastasis (hereafter, metastatic organs). Methods Between January 2010 and December 2016, consecutive patients with EGFR‐mutated NSCLC who were started on first‐line EGFR‐TKI were reviewed. The factors influencing withholding systemic chemotherapy and the post‐progression survival (PPS) after failure of EGFR‐TKI were investigated. Results A total of 393 patients were started on first‐line EGFR‐TKI during the study period. After excluding patients maintained on EGFR‐TKI or who received osimertinib targeting secondary EGFR T790M, 297 patients were included in the analysis. Among these, 180 (60.6%) received chemotherapy after failure of EGFR‐TKI (TKI‐Ct group), while the remaining 117 (39.4%) received no chemotherapy (TKI‐only group). Multivariate analysis identified older age (≥75 years: odds ratio [OR] = 0.25, 95% confidence interval [CI]: 0.11–0.43, P < 0.001), poor performance status (PS) (≥2: OR = 0.06, 95% CI: 0.03–0.15, P < 0.001), and three or more metastatic organs (OR = 0.42, 95% CI: 0.22–0.80, P = 0.008) as being significantly associated with withholding of chemotherapy after failure of EGFR‐TKI. Conclusion A relatively large number of metastatic organs and a poor PS were associated with the withholding of subsequent chemotherapy after failure of EGFR‐TKI in EGFR‐mutated NSCLC patients. Further research for patients with such a poor prognosis should be investigated in the future.